Physician profile
Jesse Martinez
NPI 1023234341
$12,366.31
in general payments reported to CMS, 2019-2025
34 companies · $2,955 in 2025
The $2,955 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,599 · 2022: $1,772 · 2023: $2,179 · 2024: $2,862 · 2025: $2,955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,979 · Education: $16.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,979.42 |
| Education | $16.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,798.15 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $1,776.06 | 2021-2025 | |
| Novo Nordisk INC | $918.73 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $843.53 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $802.91 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $738.50 | 2022-2025 | Repatha, Otezla, Evenity |
| Exact Sciences Corporation | $659.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $450.40 | 2021-2024 | Freestyle Libre 3 |
| Pfizer INC. | $401.56 | 2021-2025 | |
| Glaxosmithkline, LLC. | $348.76 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $340.23 | 2021-2025 | |
| Corcept Therapeutics | $277.50 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $222.28 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.41 | 2021-2025 | Xifaxan |
| Genentech USA, INC. | $168.01 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $161.93 | 2021-2023 | Immunocap |
| Baxter Healthcare | $149.53 | 2025 | Floseal |
| Boston Scientific Corporation | $145.73 | 2025 | Ams 700 |
| Evofem Biosciences, INC. | $119.87 | 2024 | |
| Mannkind Corporation | $114.21 | 2021 | |
| Paratek Pharmaceuticals, INC. | $107.90 | 2023-2024 | Nuzyra |
| Regeneron Healthcare Solutions, INC. | $104.43 | 2024 | |
| Dexcom, INC. | $103.13 | 2023 | Dexcom G7 Gss (161) |
| Amarin Pharma, INC. | $78.54 | 2021 | |
| Neurocrine Biosciences, INC. | $73.98 | 2023 | |
| Cipher Pharmaceuticals US LLC | $51.25 | 2025 | Spinosad, Natroba |
| Janssen Pharmaceuticals, INC | $42.08 | 2021 | |
| Novartis Pharmaceuticals Corporation | $35.70 | 2021 | |
| Merck Sharp & Dohme LLC | $32.88 | 2021-2024 | Vaxneuvance, Gardasil, Vaqta |
| Medtronic, INC. | $29.23 | 2022-2023 | Minimed 780g |
| Hologic Sales and Service, LLC | $24.31 | 2021 | |
| Sanofi Pasteur INC. | $22.74 | 2023 | |
| Cranial Technologies, INC | $19.51 | 2025 | Doc Band |
| Vanda Pharmaceuticals INC. | $19.11 | 2023 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.